Ryan McKay

Dr. Ryan McKay

Chemistry, University of Alberta, Edmonton, Alberta, Canada
orcid

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 June 2019 in Metabolites
Verified
Journal Article
Open access
PDF file
AEAbdul-Hamid Emwas
Abdul-Hamid Emwas
RRRaja Roy
Raja Roy
Ryan McKayRyan McKay
Ryan McKay
Leonardo TenoriLeonardo Tenori
Leonardo Tenori
Edoardo SaccentiEdoardo Saccenti
Edoardo Saccenti
David Scott WishartDavid Scott Wishart
David Scott Wishart
Over the past two decades, nuclear magnetic resonance (NMR) has emerged as one of the three principal analytical techniques used in metabolomics (the other two being gas chromatography coupled to mass spectrometry (GC-MS) and liquid chromatography coupled with single-stage mass spectrometry (LC-MS)). The relative ease of sample preparation, the ability to quantify metabolite levels, the high level of experimental reproducibility, and the inherently nondestructive nature of NMR spectroscopy have made it the preferred platform for long-term or large-scale clinical metabolomic studies. These advantages, however, are often outweighed by the fact that most other analytical techniques, including both LC-MS and GC-MS, are inherently more sensitive than NMR, with lower limits of detection typically being 10 to 100 times better. This review is intended to introduce readers to the field of NMR-based metabolomics and to highlight both the advantages and disadvantages of NMR spectroscopy for metabolomic studies. It will also explore some of the unique strengths of NMR-based metabolomics, particularly with regard to isotope selection/detection, mixture deconvolution via 2D spectroscopy, automation, and the ability to noninvasively analyze native tissue specimens. Finally, this review will highlight a number of emerging NMR techniques and technologies that are being used to strengthen its utility and overcome its inherent limitations in metabolomic applications.

27 August 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
WVWayne Vuong
Wayne Vuong
MKMuhammad Bashir Khan
Muhammad Bashir Khan
CFConrad Fischer
Conrad Fischer
EAElena Arutyunova
Elena Arutyunova
TLTess Lamer
Tess Lamer
MLM Joanne Lemieux
M Joanne Lemieux
The main protease, Mpro(or 3CLpro) in SARS-CoV-2 is a viable drug target because of its essential role in the cleavage of the virus polypeptide. Feline infectious peritonitis, a fatal coronavirus infection in cats, was successfully treated previously with a prodrug GC376, a dipeptide-based protease inhibitor. Here, we show the prodrug and its parent GC373, are effective inhibitors of the Mprofrom both SARS-CoV and SARS-CoV-2 with IC50values in the nanomolar range. Crystal structures of SARS-CoV-2 Mprowith these inhibitors have a covalent modification of the nucleophilic Cys145. NMR analysis reveals that inhibition proceeds via reversible formation of a hemithioacetal. GC373 and GC376 are potent inhibitors of SARS-CoV-2 replication in cell culture. They are strong drug candidates for the treatment of human coronavirus infections because they have already been successful in animals. The work here lays the framework for their use in human trials for the treatment of COVID-19.


1 March 2004 in Biochemistry
Verified
Journal Article
Closed access
KKKaren E. Kawulka
Karen E. Kawulka
TSTara Sprules
Tara Sprules
CDChristopher M. Diaper
Christopher M. Diaper
RWRandy M. Whittal
Randy M. Whittal
Ryan McKayRyan McKay
Ryan McKay
JVJohn C. C Vederas
John C. C Vederas

20 January 2016 in Journal of Proteome Research
Verified
Journal Article
Open access
AEAbdul-Hamid Emwas
Abdul-Hamid Emwas
RRRaja Roy
Raja Roy
Ryan McKayRyan McKay
Ryan McKay
DRDanielle Ryan
Danielle Ryan
LBLorraine Brennan
Lorraine Brennan
David Scott WishartDavid Scott Wishart
David Scott Wishart
NMR-based metabolomics has shown considerable promise in disease diagnosis and biomarker discovery because it allows one to nondestructively identify and quantify large numbers of novel metabolite biomarkers in both biofluids and tissues. Precise metabolite quantification is a prerequisite to move any chemical biomarker or biomarker panel from the lab to the clinic. Among the biofluids commonly used for disease diagnosis and prognosis, urine has several advantages. It is abundant, sterile, and easily obtained, needs little sample preparation, and does not require invasive medical procedures for collection. Furthermore, urine captures and concentrates many “unwanted” or “undesirable” compounds throughout the body, providing a rich source of potentially useful disease biomarkers; however, incredible variation in urine chemical concentrations makes analysis of urine and identification of useful urinary biomarkers by NMR challenging. We discuss a number of the most significant issues regarding NMR-based urinary metabolomics with specific emphasis on metabolite quantification for disease biomarker applications and propose data collection and instrumental recommendations regarding NMR pulse sequences, acceptable acquisition parameter ranges, relaxation effects on quantitation, proper handling of instrumental differences, sample preparation, and biomarker assessment.

12 February 2018 in Metabolomics
Verified
Journal Article
Open access
PDF file
AEAbdul-Hamid Emwas
Abdul-Hamid Emwas
Edoardo SaccentiEdoardo Saccenti
Edoardo Saccenti
XGXin Gao
Xin Gao
Ryan McKayRyan McKay
Ryan McKay
VSVítor Martins Dos Santos
Vítor Martins Dos Santos
David Scott WishartDavid Scott Wishart
David Scott Wishart
1H NMR spectra from urine can yield information-rich data sets that offer important insights into many biological and biochemical phenomena. However, the quality and utility of these insights can be profoundly affected by how the NMR spectra are processed and interpreted. For instance, if the NMR spectra are incorrectly referenced or inconsistently aligned, the identification of many compounds will be incorrect. If the NMR spectra are mis-phased or if the baseline correction is flawed, the estimated concentrations of many compounds will be systematically biased. Furthermore, because NMR permits the measurement of concentrations spanning up to five orders of magnitude, several problems can arise with data analysis. For instance, signals originating from the most abundant metabolites may prove to be the least biologically relevant while signals arising from the least abundant metabolites may prove to be the most important but hardest to accurately and precisely measure. As a result, a number of data processing techniques such as scaling, transformation and normalization are often required to address these issues. Therefore, proper processing of NMR data is a critical step to correctly extract useful information in any NMR-based metabolomic study. In this review we highlight the significance, advantages and disadvantages of different NMR spectral processing steps that are common to most NMR-based metabolomic studies of urine. These include: chemical shift referencing, phase and baseline correction, spectral alignment, spectral binning, scaling and normalization. We also provide a set of recommendations for best practices regarding spectral and data processing for NMR-based metabolomic studies of biofluids, with a particular focus on urine.